| Trial registration number
|
NCT04939402 |
Full text link
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT04939402
|
First author
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
Sabine Allard, phd, md
|
Contact
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
sabine.allard@uzbrussel.be
|
Registration date
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
2021-06-25
|
Recruitment status
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
Recruiting
|
Study design
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
nonRCT
|
Allocation
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
Non-randomized
|
Design
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
Single group assignment
|
Masking
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
Open label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
Prevention
|
Inclusion criteria
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
- any adult employee of the uz brussel at t1 who has been vaccinated at the uz brussel
with chadox1 ncov-19 vaccine between the 2nd of march and the 9th of march 2021 after
participating to phase 4 of the covemuz study between the 25th of january and the 12th
of february and has provided a signed informed consent.
|
Exclusion criteria
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
- uz brussel employees not active during the inclusion period (t1).
|
Number of arms
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
1
|
Funding
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
Universitair Ziekenhuis Brussel
|
Inclusion age min
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
Belgium
|
Type of patients
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
Healthy volunteers
|
Severity scale
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
N/A
|
Total sample size
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
200
|
primary outcome
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
Seroconversion;Seroprevalence
|
Notes
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov
|
Not reported
|
Arms
Last imported at : June 27, 2021, 2:30 a.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "2", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}]
|